PubMed
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence
Anisimov VN, Khavinson VK, Popovich IG, et al. Biogerontology. 2003
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 70% · Mixed 18% · Unfavorable overall 12%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 0–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 65% said they felt similar to their last entry, 38% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 21 days · Based on 17 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 68% · Mixed 16% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 168 repeat reporters
Published sources linked on the Epithalon and IGF-1 LR3 wiki pages.
PubMed
Anisimov VN, Khavinson VK, Popovich IG, et al. Biogerontology. 2003
PubMed
Khavinson VK, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003
PubMed
Khavinson VK. Bull Exp Biol Med. 2002
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Khavinson VKh, Bondarev IE, Butyugov AA, et al. Bulletin of experimental biology and medicine. 2004
PubMed
Khavinson VK, Yakovleva ND, Popuchiev VV, et al. Bull Exp Biol Med. 2001
PubMed
Khavinson VKh, Kvetnoi IM, Popuchiev VV, et al. Arkh Patol. 2001
PubMed
Khavinson VK, Konovalov SS, Yuzhakov VV, et al. Bull Exp Biol Med. 2001
PubMed
Khavinson VKh, Golubev AG. Adv Gerontol. 2002
PubMed
Khavinson V, Razumovsky M, Trofimova S, et al. Neuro Endocrinol Lett. 2002
Review Article
Khavinson VKh. Neuro Endocrinol Lett. 2002
PubMed
Khavinson V, Diomede F, Mironova E, et al. Molecules. 2020
Review Article
Rahman OF, Lee SJ, Seeds WA. J Am Acad Orthop Surg Glob Res Rev. 2026
PubMed
Baxter RC. Endocr Rev. 2011
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025
PubMed
Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025